Overview
- This week three plaintiff firms publicly filed or announced class actions accusing ARS Pharmaceuticals of misleading investors about neffy’s commercial rollout and payer access.
- The complaints allege company statements gave investors a false timeline for expanded insurance formulary coverage, including expected placement with CVS Caremark.
- The filings point to a June 24, 2026 ARS press release that said no new commercial formulary additions for neffy were issued for the July 1 cycle and note the stock fell about $2.52 per share, or 23.9%, on June 25 after that update.
- Law firms are soliciting investors to join the proposed class and warn that anyone who wants to move to be lead plaintiff must do so by October 5, 2026.
- No court has ruled on the claims; the likely next steps are competing lead‑plaintiff motions, consolidation of complaints, and early litigation such as motions to dismiss or discovery that will determine whether the allegations proceed.